PDF(Pubmed)
Abstract：
UNASSIGNED: To describe the early experiences of patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) whose treatment was switched to faricimab from other anti-vascular endothelial growth factor (VEGF) agents.
UNASSIGNED: This is a prospective cohort of eyes with nAMD and PCV that were previously treated with anti-VEGF agents other than faricimab. We evaluated visual acuity (VA), central subfield thickness (CST), macular volume (MV), pigment epithelial detachment (PED) height, and choroidal thickness (CT) after one administration of faricimab. Where present, fluid was further evaluated according to intraretinal fluid (IRF), subretinal fluid (SRF), or within PED.
UNASSIGNED: Seventy-one eyes from 71 patients were included (45.07% PCV and 54.93% typical nAMD). The mean [standard deviation (± SD)] VA, CST, and MV improved from 0.50 logMAR (± 0.27 logMAR) to 0.46 logMAR (± 0.27 logMAR) (p = 0.20), 383.35 µm (± 111.24 µm) to 322.46 µm (± 103.89 µm (p < 0.01), and 9.40 mm3 (± 1.52 mm3) to 8.75 mm3 (± 1.17 mm3) (p < 0.01) from switch to post switch visit, respectively. The CT reduced from 167 µm (± 151 µm) to 149 µm (± 113 µm) (p < 0.01). There was also a significant reduction in the maximum PED height between visits [302.66 µm (± 217.97 µm)] and the post switch visit [236.66 µm (± 189.05 µm); p < 0.01]. This difference was greater in PEDs that were predominantly serous in nature. In the eyes with typical nAMD (n = 39), improvements were significant for CST, MV, CT, and PED. In the eyes with PCV (n = 32), only reductions in CT were statistically significant, while VA, CST, MV, and PED only showed numerically smaller improvements. One patient developed mild vitritis without vasculitis, which resolved with topical steroids with no sequelae.
UNASSIGNED: In our case series of Asian nAMD patients, switching to faricimab was associated with a stable VA and meaningful anatomical improvements, particularly with typical nAMD subtypes.
UNASSIGNED: This is a prospective cohort of eyes with nAMD and PCV that were previously treated with anti-VEGF agents other than faricimab. We evaluated visual acuity (VA), central subfield thickness (CST), macular volume (MV), pigment epithelial detachment (PED) height, and choroidal thickness (CT) after one administration of faricimab. Where present, fluid was further evaluated according to intraretinal fluid (IRF), subretinal fluid (SRF), or within PED.
UNASSIGNED: Seventy-one eyes from 71 patients were included (45.07% PCV and 54.93% typical nAMD). The mean [standard deviation (± SD)] VA, CST, and MV improved from 0.50 logMAR (± 0.27 logMAR) to 0.46 logMAR (± 0.27 logMAR) (p = 0.20), 383.35 µm (± 111.24 µm) to 322.46 µm (± 103.89 µm (p < 0.01), and 9.40 mm3 (± 1.52 mm3) to 8.75 mm3 (± 1.17 mm3) (p < 0.01) from switch to post switch visit, respectively. The CT reduced from 167 µm (± 151 µm) to 149 µm (± 113 µm) (p < 0.01). There was also a significant reduction in the maximum PED height between visits [302.66 µm (± 217.97 µm)] and the post switch visit [236.66 µm (± 189.05 µm); p < 0.01]. This difference was greater in PEDs that were predominantly serous in nature. In the eyes with typical nAMD (n = 39), improvements were significant for CST, MV, CT, and PED. In the eyes with PCV (n = 32), only reductions in CT were statistically significant, while VA, CST, MV, and PED only showed numerically smaller improvements. One patient developed mild vitritis without vasculitis, which resolved with topical steroids with no sequelae.
UNASSIGNED: In our case series of Asian nAMD patients, switching to faricimab was associated with a stable VA and meaningful anatomical improvements, particularly with typical nAMD subtypes.
摘要：
■描述新生血管性年龄相关性黄斑变性（nAMD）和息肉状脉络膜血管病变（PCV）患者的早期经历，这些患者的治疗从其他抗血管内皮生长因子（VEGF）药物转为法利单抗。
■这是一个前瞻性的nAMD和PCV患者队列，这些患者先前接受了法利单抗以外的抗VEGF药物治疗。我们评估了视力（VA），中心子场厚度（CST），黄斑体积（MV），色素上皮脱离（PED）高度，和脉络膜厚度（CT）在一次施用法利单抗后。Wherepresent,根据视网膜内流体(IRF)进一步评估流体，视网膜下液（SRF），或PED内。
■纳入71例患者的71只眼（45.07%的PCV和54.93%的典型nAMD）。平均值[标准偏差(±SD)]VA，CST,MV从0.50logMAR（±0.27logMAR）提高到0.46logMAR（±0.27logMAR）（p=0.20），383.35µm(±111.24µm)至322.46µm(±103.89µm(p<0.01),和9.40mm3(±1.52mm3)至8.75mm3(±1.17mm3)(p<0.01),分别。CT从167µm（±151µm）降低到149µm（±113µm）（p<0.01）。在访视[302.66µm（±217.97µm）]和转换后访视[236.66µm（±189.05µm）之间，最大PED高度也显着降低；p<0.01]。在本质上主要是浆液性的PED中，这种差异更大。在典型nAMD（n=39）的眼睛中，对于CST来说，改进是显著的，MV,CT,PED。在PCV（n=32）的眼中，只有CT的减少有统计学意义，而VA,CST,MV,和PED仅显示出数值较小的改进。一名患者出现轻度玻璃体炎，无血管炎，用局部类固醇解决，没有后遗症。
■在我们的亚洲nAMD患者系列病例中，转换为法利单抗与稳定的VA和有意义的解剖学改善相关，特别是典型的nAMD亚型。
■这是一个前瞻性的nAMD和PCV患者队列，这些患者先前接受了法利单抗以外的抗VEGF药物治疗。我们评估了视力（VA），中心子场厚度（CST），黄斑体积（MV），色素上皮脱离（PED）高度，和脉络膜厚度（CT）在一次施用法利单抗后。Wherepresent,根据视网膜内流体(IRF)进一步评估流体，视网膜下液（SRF），或PED内。
■纳入71例患者的71只眼（45.07%的PCV和54.93%的典型nAMD）。平均值[标准偏差(±SD)]VA，CST,MV从0.50logMAR（±0.27logMAR）提高到0.46logMAR（±0.27logMAR）（p=0.20），383.35µm(±111.24µm)至322.46µm(±103.89µm(p<0.01),和9.40mm3(±1.52mm3)至8.75mm3(±1.17mm3)(p<0.01),分别。CT从167µm（±151µm）降低到149µm（±113µm）（p<0.01）。在访视[302.66µm（±217.97µm）]和转换后访视[236.66µm（±189.05µm）之间，最大PED高度也显着降低；p<0.01]。在本质上主要是浆液性的PED中，这种差异更大。在典型nAMD（n=39）的眼睛中，对于CST来说，改进是显著的，MV,CT,PED。在PCV（n=32）的眼中，只有CT的减少有统计学意义，而VA,CST,MV,和PED仅显示出数值较小的改进。一名患者出现轻度玻璃体炎，无血管炎，用局部类固醇解决，没有后遗症。
■在我们的亚洲nAMD患者系列病例中，转换为法利单抗与稳定的VA和有意义的解剖学改善相关，特别是典型的nAMD亚型。
